Clinical Trial Update: Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating Erlotinib hydrochloride for prevention of liver cancer in patients with cirrhosis; study phases completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hepatocellular Carcinoma

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cirrhosis, Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-02-25